Enliven Therapeutics (ELVN)

• Market cap: $1.64B
• 1 day: -1.37%
• 5 days: -7.84%
• 1 month: 4.82%
• 3 months: 61.98%
• 6 months: 48.62%
• Year to date: 76.25%
• 1 year: 30.18%
• 5 years: -34.6%
• 10 years: -54.35%
• Sector: Healthcare
• Industry: Biotechnology

About: Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Employees: 60